Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Receivables: 2019-2025

Historic Receivables for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $43.6 million.

  • Pharming Group N.V's Receivables fell 9.53% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.8 million, marking a year-over-year increase of 7.79%. This contributed to the annual value of $56.4 million for FY2024, which is 16.80% up from last year.
  • Pharming Group N.V's Receivables amounted to $43.6 million in Q3 2025, which was down 18.23% from $53.3 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Receivables registered a high of $56.4 million during Q4 2024, and its lowest value of -$5.5 million during Q2 2023.
  • For the 3-year period, Pharming Group N.V's Receivables averaged around $41.4 million, with its median value being $47.5 million (2025).
  • As far as peak fluctuations go, Pharming Group N.V's Receivables soared by 1,061,872.31% in 2022, and later tumbled by 91.33% in 2023.
  • Pharming Group N.V's Receivables (Quarterly) stood at $32.3 million in 2021, then dropped by 11.16% to $28.7 million in 2022, then soared by 68.09% to $48.3 million in 2023, then rose by 16.80% to $56.4 million in 2024, then fell by 9.53% to $43.6 million in 2025.
  • Its last three reported values are $43.6 million in Q3 2025, $53.3 million for Q2 2025, and $47.5 million during Q1 2025.